Navigation Links
Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
Date:1/4/2008

FRAZER, Pa., Jan. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that Frank Baldino, Jr., Ph.D., Chairman and CEO will present at the JP Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, CA. Dr. Baldino will deliver a one hour presentation on Tuesday, January 8, 2008 beginning at 2:00 p.m. Pacific Time (11 a.m. Eastern Time).

Live Web Cast and Archived Replay

Members of the financial and investment community, the media and other interested parties can access a live web cast of the presentation through the investor relations section of the company's website http://www.cephalon.com. Following the live presentation, a replay of the presentation will be available for two weeks on the company's website.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous produc
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
2. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
5. DaVita Inc. to Present at JPMorgan Healthcare Conference
6. Hologic to Present at the 26th Annual JP Morgan Healthcare Conference
7. WebMD to Present at Upcoming Investor Conferences
8. Neurochem to present at JPMorgan Healthcare Conference
9. Cepheid to Present at the Needham Tenth Annual Growth Stock Conference
10. MedCath Corporation to Present at the 26th Annual JPMorgan Healthcare Conference
11. Insulet Corporation to Present at the JPMorgan Healthcare Conference on January 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... together with the Chinese Thoracic Society (CTS) announced ... CHEST World Congress 2016 will be held in ... sleep medicine from around the world are expected ... 2016. , CHEST World Congress 2016 will ... keynote addresses, presentations by leading health-care experts, and ...
(Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
(Date:9/18/2014)... A group of international scientists have developed a new ... here . , The Wildlife Conservation Society (WCS)-led ... Tropical Diseases , describes the use of fecal samples ... have been exposed to the virus. This represents a ... can potentially change the way Ebola virus is studied ...
(Date:9/18/2014)... guidelines recommending that elderly men should not be routinely ... according to a new study led by researchers at ... letter online in JAMA Internal Medicine , focused ... to test for prostate cancer., "We found that the ... of elderly men in particular has been minimal at ...
(Date:9/18/2014)... New York (PRWEB) September 18, 2014 ... the easy availability of products such as smart phones, ... been observed in the way mobile devices are viewed ... or record personal data to becoming a mode for ... technology has come a long way. , ...
Breaking Medicine News(10 mins):Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4
... more often than previously believed, study finds , , TUESDAY, ... infections are more common, both in and out of ... , Methicillin-resistant Staphylococcus aureus (MRSA) infections are the top ... in hospitals and can result in severe and even ...
... Even though Americans pick up their,toothbrushes for a ... cleaning of their own. Celebrity Dentist Dr. Bill Dorfman ... survey conducted by the,Philips Sonicare brand shows dirty brushes ... this report from Philips (NYSE: PHG ) at:, ...
... Inc. (Nasdaq: GTIV ), the nation,s largest provider ... it has,scheduled a conference call and web cast on ... operating results for the third quarter and nine,months ended ... news,release the morning of November 1 before pre-market trading. ...
... Annual Wells Fargo Walk of Ages ... Fundraiser, RESEDA, ... name of "Walker" in the United States to either,join or give a dollar ... in Reseda. According to official census records there,are 663,233 people in the country ...
... ST. LOUIS, Oct. 16 Young Innovations, Inc.,(Nasdaq: ... third quarter,earnings results with a live and on-demand web ... am Central Time. A live audio,broadcast of the call ... to the live audio broadcast,will also be available through ...
... Oct. 16 /PRNewswire-FirstCall/ - Beanstalk Capital Ltd.,("Beanstalk") ... entered into an arm,s,length arrangement agreement dated ... Therapeutics Inc. ("iCo"). The proposed transaction,(the "Arrangement"), ... a capital pool company. Under the Arrangement,iCo ...
Cached Medicine News:Health News:Drug-Resistant Staph a Widespread Threat 2Health News:Drug-Resistant Staph a Widespread Threat 3Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 2Health News:Gentiva(R) Health Services Schedules Third Quarter Earnings Call and Web Cast for Thursday, November 1, 2007 3Health News:FORGET THE JONESES, This is All About Keeping up With the Walkers as the Los Angeles Jewish Home Sends Out an Invite to Everyone Named 'Walker' in the United States 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 2Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 3Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 4Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 5Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 6Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 7Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 8Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 9Health News:Beanstalk Capital Ltd. enters into arrangement agreement with iCo Therapeutics Inc. 10
(Date:9/18/2014)... and PLAINSBORO, N.J. , ... its support of the National Hemophilia Foundation,s (NHF) ... which provides support to people with hemophilia and ... psychosocial challenges that can impede disease management. The ... Communication With Your Provider About Pain , ...
(Date:9/18/2014)... , Sept. 18, 2014 Australian biomarker ... important US trial of its MiStat™ prostate cancer screening ... (FDA) regulatory approval upon completion. Minomic,s proprietary ... the presence of a proprietary biomarker known as the ... of prostate cancer cells. Researchers at ...
(Date:9/18/2014)... Md. , Sept. 18, 2014  Spectrum Pharmaceuticals, ... with fully integrated commercial and drug development operations with ... Pharmaceuticals, Inc. (Nasdaq: CASI ), a biopharmaceutical ... innovative therapeutics addressing cancer and other unmet medical needs ... China , announce the signing of ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10
... DALLAS , June 21, 2010 ... store. , , , ... Cardiovascular Devices Market Outlook to 2016 (, http://www.reportsandreports.com/market-reports/netherlands-cardiovascular-de ,vices-market-outlook-to-2016/) , ... (Due to the length of these ...
... 21 Medco Health Solutions, Inc. (NYSE: MHS ) and ... joint venture with a long-term goal of improving patient health and helping to ... , , ... , , ...
Cached Medicine Technology:Cardiovascular Devices Market Outlook June Update by ReportsandReports 2Cardiovascular Devices Market Outlook June Update by ReportsandReports 3Cardiovascular Devices Market Outlook June Update by ReportsandReports 4Cardiovascular Devices Market Outlook June Update by ReportsandReports 5Cardiovascular Devices Market Outlook June Update by ReportsandReports 6Cardiovascular Devices Market Outlook June Update by ReportsandReports 7Cardiovascular Devices Market Outlook June Update by ReportsandReports 8Cardiovascular Devices Market Outlook June Update by ReportsandReports 9Cardiovascular Devices Market Outlook June Update by ReportsandReports 10Medco and Celesio Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs 2Medco and Celesio Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs 3Medco and Celesio Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs 4Medco and Celesio Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs 5Medco and Celesio Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs 6Medco and Celesio Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs 7
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: